Orca Bio’s TREGZI™ Wins FDA Nod for Hematological Malignancies
Event summary
- Orca Bio’s TREGZI™ received FDA approval on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation.
- The therapy improved chronic GVHD-free survival to 78% compared to 38% with conventional alloHSCT in the Precision-T Phase 3 study (n=187).
- TREGZI™ combines HSPCs, Tregs, and Tcons to reduce GVHD and accelerate immune reconstitution.
- Orca Bio completed Series F financing led by Lightspeed Venture Partners earlier this year.
The big picture
Orca Bio’s FDA approval marks a significant milestone in precision-engineered cell therapy, addressing a critical unmet need in transplant medicine. The company’s proprietary platform leverages single-cell precision to create uniquely defined products, positioning it as a leader in the curative allogeneic cell therapy space. With Series F financing secured, Orca Bio is well-capitalized to drive commercialization and potentially expand into autoimmune disease indications.
What we're watching
- Commercialization Pace
- How quickly Orca Bio can scale manufacturing and distribution to meet demand for TREGZI™.
- Competitive Response
- Whether existing players in cell therapy will accelerate their own pipeline developments in response.
- Long-term Efficacy
- The durability of TREGZI™’s survival benefits beyond the 12-month endpoint observed in clinical trials.
Related topics